Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinomaJ I Clark, E R Gaynor, B Martone, et al.Annals of Internal Medicine|December 15, 1988
The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cellsE R Gaynor, L Vitek, L Sticklin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaJ P Dutcher, E R Gaynor, D H Boldt, et al.The New England Journal of Medicine|April 8, 1993
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomaR I Fisher, E R Gaynor, S Dahlberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809R I Fisher, B W Dana, M LeBlanc, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma StudyR I Fisher, E R Gaynor, S Dahlberg, et al.Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group StudyE R Gaynor, J M Unger, T P Miller, et al.Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.Pageof 3